PDD Holdings Inc. American Depositary Shares vs Regeneron Pharmaceuticals Inc — how do they compare? PDD Holdings Inc. American Depositary Shares trades at $79.07 (market cap $111.74B), while Regeneron Pharmaceuticals Inc trades at $739.58 (market cap $76.40B). The key difference: PDD Holdings Inc. American Depositary Shares is the larger of the two by market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while PDD Holdings Inc. American Depositary Shares pays none. Which is the better fit depends on your goals.
| PDD | REGN | |
|---|---|---|
Market Cap | $111.74B | $76.40B |
Volume | 4,029,869 | 626,381 |
Sector | Consumer Cyclical | Health |
52-Week High | $138.13 | $852.03 |
52-Week Low | $73.30 | $557.73 |
Enterprise Value | $44.39B | $71.12B |
Typical Hold Time | — | 107 Days |
Dividend Yield | — | 0.51% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.
The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
PDD Holdings is a multinational commerce group that owns and operates a portfolio of businesses. Its sourcing, logistics, and fulfillment network supports those businesses and their commerce operations.
Read more on PDD →Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →